Context Invasive bladder cancer is a frequently occurring disease with a high mortality rate
despite optimal treatment. The European Association of Urology (EAU) Muscle-invasive and …

PURPOSE: Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and
cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional …

Purpose: Platinum-based chemotherapy remains the standard treatment for advanced
urothelial carcinoma by inducing DNA damage. We hypothesize that somatic alterations in …

Bladder cancer occurs in the majority of cases in males. It represents the seventh most
common cancer and the ninth most common cause of cancer deaths for men. Transitional …

Introduction Nectin-4 is a tumor-associated antigen overexpressed in urothelial carcinoma
and several other malignancies. It has emerged as a compelling target for novel tumor …

BACKGROUND: Nephroureterectomy alone fails to adequately treat many patients with
advanced upper tract urothelial carcinoma (UTUC). Perioperative platinum-based …

OBJECTIVES: This phase 2 randomized study compared the toxicity and assessed the
efficacy of gemcitabine–cisplatin (GP) and gemcitabine–carboplatin (GC) in patients with …

Purpose There is no standard treatment for patients with advanced urothelial cancer who
are ineligible (“unfit”) for cisplatin-based chemotherapy (CHT). To compare the activity and …

Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced
Unresectable or Metastatic Urothelial Cancer - PMC Back to Top Skip to main content NIH NLM …

Urothelial cancer of the bladder is the 4th most common malignancy in American men and
the 9th most common in women. Although it is a chemosensitive disease, advanced bladder …